The relation of radiological tumor volume response to histological response and outcome in patients with localized Ewing Sarcoma

Lianne M. Haveman1,2 | Andreas Ranft3,4 | Henk vd Berg1 | Anne Smets5 | Jarmila Kruseova6 | Ruth Ladenstein7 | Benedicte Brichard8 | Michael Paulussen9 | Thomas Kuehne10 | Heribert Juergens4,11 | Stephanie Klco-Brosius3,4 | Uta Dirksen3,4 | Johannes H.M. Merks1

1Emma Children’s Hospital, Department of Pediatric Oncology, Academic Medical Center, Amsterdam, The Netherlands
2Prinses Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
3Department of Pediatric Hematology and Oncology, University of Essen, Essen, Germany
4Coordinating Center for Clinical Trials, Muenster, Germany
5Department of Radiology, Academic Medical Center, Amsterdam, The Netherlands
6Department of Pediatric Oncology, University Hospital Motol, Prague, Czech Republic
7Children’s Cancer Research Institute, Vienna, Austria
8Saint Luc University Hospital, Department of Pediatric Hematology and Oncology, University of Louvain, Datteln, Belgium
9Witten/Herdecke University, Vestische Kinder- und Jugendklinik, Datteln, Germany
10Department of Pediatric Oncology and Haematology, University Children Hospital, Basel, Switzerland
11Department of Pediatric Hematology and Oncology, University Children’s Hospital, Muenster, Germany

Correspondence
Lianne M. Haveman, Prinses Maxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht, The Netherlands. Email: l.m.haveman-3@prinsesmaximacentrum.nl

Funding information
ERA-Net-TRANSCAN, Grant/Award Number: 01KT1310; Dutch Kika Foundation (Children Cancer Free); Deutsche Krebshilfe (DKH)1, Grant/ Award Number: 08128; European Ewing Consortium, Grant/Award Number: 602856-2

Abstract
Background: Magnetic resonance imaging (MRI) is the modality of choice for local staging and response evaluation of Ewing sarcoma (EwS). Aim of this study was to determine the relevance of tumor volume response (TVR) in relation to histological response (HisRes) and survival, in order to evaluate if early modification of chemotherapy might be indicated in patients with inadequate TVR.

Methods: Three dimensional (3D)-tumor volume data at diagnosis, during early induction phase (1-3 courses of chemotherapy; n = 195) and/or late induction phase (4-6 courses; n = 175) from 241 localized patients were retrospectively analyzed. A distinction was made between adequate response (reduction ≥67%) and inadequate response (reduction <67% or progression). Correlations between TVR, HisRes, event free survival (EFS), and overall survival (OS) were analyzed using chi-square tests, log-rank tests, and the Cox-regression model.

Results: Early adequate TVR, noted in 41% of patients, did not correlate with EFS (P = 0.92) or OS (P = 0.38). During late induction phase 62% of patients showed an adequate TVR. EFS for patients with late adequate TVR was better (78%) than for those with
INTRODUCTION

Ewing sarcoma (EwS) is the second most common malignant bone tumor in childhood, predominantly affecting children and young adults. Histologically, small blue round cells are noted. Up to 95% of patients harbor the characteristic chromosomal 11q22q translocation. The backbone of EwS treatment is induction chemotherapy that treats micrometastatic disease and reduces tumor volume to facilitate surgical procedures. Induction chemotherapy is followed by local therapy (surgery and/or radiotherapy) and maintenance chemotherapy. This multimodal treatment has greatly improved survival rate for EwS patients. Overall survival (OS) for patients with localized disease is approximately 70%-75%; however, still below 30% for patients with metastatic disease. In the daily clinic, there is a need for prognostic factors that give an early indication whether response of the tumor to induction chemotherapy is adequate or whether chemotherapy should be adjusted in case of inadequate response. Histological response (HisRes) has been identified as a prognostic factor for outcome; however, histological response is known late in the treatment, after induction chemotherapy and after local therapy has been performed, and cannot be identified in patients only receiving radiotherapy.

At diagnosis of EwS there is often major soft tissue involvement, which substantially contributes to the total tumor volume. After induction chemotherapy, there is usually a decrease in the soft tissue component, whereas the bony component shows little regression, probably due to the slow regression of the osteoid matrix. Based on the superior assessment of intramedullary and soft tissue extension, magnetic resonance imaging (MRI) is considered to be the modality of choice for local staging and response evaluation. Early modification of chemotherapy or an intensification of radiotherapy dosage could be potential options for patients with inadequate radiological response noted during early or late induction chemotherapy. Modification could exist of changing to second line agents or the addition of new, often targeted, agents.

METHODS

2.1 Study population

Data from consecutive Ewing sarcoma patients included in the EE99 trial between September 1999 and September 2009 were analyzed. Of these only patients with localized disease and all patients whose data contained 3D tumor volume measurements both at diagnosis and at least once during induction chemotherapy were included in the study. Patients who had received local therapy earlier than per protocol were excluded from the analysis. Primary EwS was confirmed by pathology and molecular diagnostics in all patients. All patients and/or legal guardians had given informed consent prior to study entry.

2.2 Treatment

The EE99 protocol mandated 6 courses of induction chemotherapy consisting of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE). Following local therapy, a risk-adapted chemotherapy was administered. Protocol treatment details have been previously published.

2.3 Definitions

2.3.1 Tumor volume

Three-dimensional tumor volume was calculated from MRI measurements (anteroposterior dimension x transverse
x craniocaudal dimension). In the EE99 study a correction factor (F) was applied to elliptically shaped tumors \((F = \pi/6 = 0.52)\) and to cylindrically shaped tumors \((F = \pi/4 = 0.785)\). For all other tumor shapes, a correction factor of 0.63 \((F = \pi/5)\) was applied. The same correction factor used for the MRI at diagnosis was used for subsequent MRIs. Changes in tumor volume were expressed as percentage involution. Adequate response (reduction ≥67%) and inadequate response (reduction <67% or progressive disease) were delineated in line with cutoff values for partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) response assessment.\(^\text{1819}\)

### 2.3.2 Histological response

Following induction chemotherapy, local therapy was performed. In patients who underwent surgery, the grade of histopathological response, that is, the percentage of viable tumor cells in the specimen, was determined according to the Salzer-Kuntschik classification.\(^\text{20}\) A good response was defined as having less than 10% viable tumor cells (grade 1: no vital cells, grade 2: 1%-4% vital cells, grade 3: 5%-9% vital cells). A poor response was defined as having more than 10% viable tumor cells (grade 4: 10%-50% cells, grade 5/6: >50% vital cells).

### 2.3.3 Survival

EFS time was defined as the interval between the first day of the first VIDE course and the date of first event or death. In the absence of events, patients were censored on the date of their most recent consultation. An event was defined as progressive disease, relapsed disease (local or metastatic), secondary malignancy, or death from any cause. OS was defined as the time from the first day of the first VIDE course until death from any cause. Patients with progressive disease (PD) at time of TVR assessment were excluded from analysis, as PD on therapy is known to be associated with poor outcome.

### 2.4 Statistical analyses

Statistical analyses were performed using SPSS statistics 22 (IBM Corporation, Armonk, NY) and SAS 9.2 (SAS Institute, Cary, NC) software packages. EFS and OS were calculated using the Kaplan–Meier method. A log-rank test was performed to determine statistical differences in the distribution of survival. Univariate comparisons between groups of patients and statistical significance were accomplished using log-rank and chi-square tests. Multivariate test procedures applied Cox and logistic regression analyses. The significance level was set at \(P < 0.05\) (two-sided). Missing data were handled using list wise deletion.

### RESULTS

From in total 1435 patients included in the EE99 trial, 907 patients had localized EwS. In 246 of the 907 patients the 3D tumor volume was calculated from MRI measurements taken at diagnosis and at least once during induction chemotherapy. Two patients who had received local or systemic therapy earlier than per protocol and 3 patients who had received initial surgery were excluded from analysis, so ultimately 241 patients were included in the study (Figure 1). Table 1 shows the clinical baseline characteristics of these patients; these characteristics are consistent with previously published reports;\(^\text{21,22}\) therefore, this study can be considered representative for the EE99 study cohort.

In 129 of 241 included patients, 3D-tumor volume measurement was performed at diagnosis, during early induction (course 1-3) and during late induction phases (course 4-6). If more than one MRI was performed during the early and/or late induction phase, only the data from the latest MRI were used. In 66 patients, an MRI was performed at diagnosis and only during early induction phase; in 46 patients, an MRI was done at diagnosis and only during late induction phase. For patients whose response was not measured with an MRI during the early induction phase \((n = 46)\) or late induction phase \((n = 66)\) other imaging modalities (often CT-scan or ultrasound) were used for response assessment at these time points; these assessments were not reported in 3D. Ultimately, TVR was determined in 195 patients during early induction phase, and in 175 patients during late induction phase (Figure 1).

In patients with early TVR measurement \((n = 193; excluding 2 patients with PD)\) median tumor reduction was 62%. In 80/193 patients \((=41\%\)\), an adequate TVR was observed (median reduction = 83%). In the group with inadequate TVR \((115/193 patients = 59\%)\) the median reduction was 41%. During late induction phase the median reduction compared to diagnosis was 77% \((n = 172\); excluding 3 patients with PD). Adequate TVR was observed in 108/172 patients \((=62\%; median reduction 88\%)\). In the 67/172 patients with an inadequate TVR the median reduction was 40%.

Of the 129 patients who had MRIs during both early and late induction phases, 4 patients showed progressive disease at time of late response assessment compared to their early response assessment. Overall, progression was observed in 9/241 patients (3.7%) during induction chemotherapy.

### 3.1 Combined evaluation of radiological and histological response

Local resection was performed in 220/241 patients (91%); 151 of these 220 patients (70%) showed a good HisRes (see also Table 1). Table 2 illustrates the TVR during early and late induction chemotherapy in relation with the HisRes
determined in the patient group who underwent local resection. In the patients with early TVR measurement, 178/195 patients (91%) underwent local resection; however, histological data from 3/178 patients were missing; 122/175 (70%) of the remaining 175 patients showed a good HisRes. Of the 175 patients with TVR measurement during late induction phase, 161/175 (91%) underwent local resection; HisRes of 1 patient was missing. 111/160 patients (69%) showed a good HisRes. No correlation could be found between either early TVR ($P = 0.92$) or late TVR ($P = 0.63$) and histological response.

### 3.2 Factors related to outcome

#### 3.2.1 Radiological response and survival

Median follow-up was 4.49 years (range 0.12-13.2). Overall, 3-year EFS was 0.71 (SE = 0.03) and OS 0.77 (SE = 0.03). This is in line with survival data previously reported from localized EwS patients in the EE99 trial.\(^{21}\)

#### 3.2.2 Early TVR measurement and survival

For the patient group with early TVR measurements available, survival data were known from 194/195 patients. In 79/194 (41%) of the patients, an adequate TVR was observed and 3-year EFS was 0.74 (SE 0.05). In patients with early inadequate response, EFS was 0.72 (SE 0.04) ($P = 0.90$). Three-year OS was 0.74 (SE 0.05) and 0.82 (SE 0.04), respectively ($P = 0.37$) (Table 2; Figure 2A).

#### 3.2.3 Late TVR and survival

In the patient group with late TVR measurements available survival data from 174/175 patients were known. In 61.5% of these patients an adequate TVR was observed; the associated 3-year EFS was 0.78 (SE 0.04) in contrast to 0.61 (SE 0.06) for patients with inadequate TVR ($P = 0.013$). Three-year OS rate for patients with adequate TVR was 0.80 (SE 0.04) compared to 0.69 (SE 0.04) for patients with inadequate TVR ($P = 0.26$) (Table 2; Figure 2B).

### 3.3 Histological response and survival

A good HisRes was observed in 151/216 patients (70%); associated 3-year EFS was 0.77 (SE 0.04), whereas EFS was 0.54 (SE 0.07) in patients with poor HisRes ($P = 0.001$). Three-year OS was 0.84 (SE 0.03) and 0.61 (SE 0.06), respectively ($P = 0.001$) (Figure 3).
3.4 | Other factors associated with outcome

Fifty-six per cent of patients had a tumor volume <200 mL; associated 3-year EFS was 0.78 (SE 0.04); significantly better ($P = 0.005$) than EFS for 105 patients with an initial tumor volume ≥200 mL (EFS 0.62; SE 0.05). OS was 0.80 (SE 0.04) in patients with an initial tumor volume <200 mL compared to 0.72 (SE 0.05) for patients with a tumor volume >200 mL ($P = 0.007$).

No statistical difference ($P = 0.66$) was detected in EFS and OS between patients with osseous EwS (EFS 0.73; (SE 0.03); OS 0.77 (SE 0.03)) and extra-osseous EwS (EFS 0.64; (SE 0.10); OS 0.64 [SE 0.1] [$P = 0.33$]).

Three-year EFS was 0.59 (SE 0.07) for patients with pelvic lesions. This was lower ($P = 0.029$) than EFS for EwS patients with other locations (EFS 0.73; (SE 0.03). OS was 0.66 (SE 0.07) and 0.80 (SE 0.03), respectively ($P = 0.04$). Patients <15 years of age had higher 3-year EFS than patients ≥15 years: 0.77 (SE 0.04) compared to 0.64 (SE 0.05; $P = 0.04$). Three-year OS was 0.83 (SE 0.04) and 0.70 (SE 0.04), respectively ($P = 0.007$). Three-year EFS was 0.66 (SE 0.04) for males and 0.79 (SE 0.04) for females ($P = 0.03$). OS was 0.74 (SE 0.04) and 0.81 (SE 0.04), respectively ($P = 0.26$).

Surgery was radical in 164/214 patients (77%); marginal in 39/214 (18%) and intraloskeletal in 11 patients (5%). Three-year EFS was 0.73 (SE 0.04), 0.63 (SE 0.78), and 0.72 (SE 0.14), respectively ($P = 0.65$). Three-year OS was 0.80 (SE 0.03), 0.66 (SE 0.08), and 0.70 (SE 0.14), respectively ($P = 0.21$).

3.5 | Multivariate analysis

Based on the factors associated with a significantly inferior 3-year EFS in univariate analysis, a multivariate analysis was
performed. Detailed results are shown in Table 3. A poor histological response after induction chemotherapy, a late 3D-TVR and pelvic site were independent predictors for inferior EFS. For OS, poor HisRes and pelvic site were independent predictors ($P < 0.05$; late inadequate TVR: $P = 0.10$).

4 | DISCUSSION

Radiological response to chemotherapy as a prognostic factor for outcome has been described in several studies. In this study, we analyzed three-dimensional tumor volume response in a large series of patients uniformly treated according to the Euro Ewing 1999 protocol to evaluate if early modification of chemotherapy could be an option in patients with an early inadequate TVR. However, we showed that early TVR is not related to prognosis nor to HisRes. Therefore, modification of chemotherapy in response to inadequate early TVR may not be justifiable. However, we did find that late inadequate TVR, poor HisRes and pelvic tumor location are independently associated with poor prognosis.

Studies concerning radiological TVR and correlation with survival were performed in small patient cohorts and showed inconsistent results. In this respect, the large number of EwS patients included in our study is novel and adds to the available evidence. Limitations of this study include its retrospective nature; volume measurement was not centrally reviewed and a limited sample size of included patients when compared to the total number of patients included in the Euro Ewing 99 trial.

TVR may not adequately reflect the complex histological changes resulting from response to chemotherapy. Therefore, besides TVR, also the residual extramedullary tumor volume, calcification of residual tumor in soft tissue and medullary cavity, T2 signal variations, diffusion weighted imaging, and fludeoxyglucose positron emission tomography have been investigated as potential markers for response. Taking also (some of) these factors into account, a better prediction of tumor response in early induction might be possible. There is some debate as to which type of measurement (3D/2D/1D) is most valuable in assessing radiological response in solid tumors. Three-dimensional tumor measurement has been shown to be more sensitive and accurate than 1D or 2D assessment in patients with other solid tumors, whereas another study could not show a difference between 3D and 1D RECIST in rhabdomyosarcoma. Three-dimensional TVR sensitivity might be more evident for tumors in which the axial tumor area changes more than the longitudinal dimension, which is commonly seen in bone tumors. Aghighi et al compared 1D, 2D, and 3D tumor measurements with clinical outcomes for EwS patients. Three-dimensional tumor measurement was shown to be superior, and a higher correlation with clinical outcome was described.
In our study, 41% of patients achieved adequate TVR during the early phase of induction therapy and 62% during late induction phase. These percentages are slightly better than the TVR reported by Pan et al.\textsuperscript{13} who examined 66 localized and metastatic EwS patients prior to surgery. Nearly 40% of patients achieved at least partial remission (PR) according to RECIST criteria. An important question in daily clinical practice is whether early modification of chemotherapy is warranted in patients with early inadequate radiological tumor volume response. None of the previously published studies focused on TVR during early induction phase, where results of our study now show that TVR during early induction phase does not correlate with survival, and therefore modification of chemotherapeutic regimen should not be based on TVR during early induction phase. However, 3-year EFS was higher for patients with adequate TVR measured late during induction chemotherapy, compared to patients with inadequate response at this time point. Furthermore, adequate TVR during either early or late chemotherapy induction phases was not a predictive marker for HisRes. This is in agreement with the observations of Pan et al.\textsuperscript{13} Abudu et al found a significant relationship between necrosis and
3D-TVRI2 however, this study included only 50 EwS patients, both localized and metastatic, and used MRI or CT-scan to determine TVR.

Similar to other studies,4,11,12,32 we found that poor HisRes to induction chemotherapy correlated with poor outcome. In addition to poor HisRes and late inadequate TVR, initial tumor volume >200 ml, age older than 15 years, pelvic location and male gender all appeared to be bad prognostic factors as determined with univariate analysis. These are all well-known unfavorable prognostic factors.2,3,21,22,32 Multivariate analysis revealed that poor HisRes, pelvic location and late inadequate TVR were independently associated with poor prognosis. Based on EFS, patients with late inadequate TVR or poor HisRes on standard therapy, as a result of intrinsic tumor resistance to applied chemo therapeutic agents, could benefit from a more augmented therapy. For patients who receive radiotherapy only and therefore lack histological response as prognostic marker, late TVR may help to adequately stratify those patients for subsequent chemotherapy.

In conclusion, based on survival data, modifying chemotherapy based on inadequate early TVR may not be justifiable; however, patients with late-phase inadequate TVR might benefit from augmented treatment.

ACKNOWLEDGMENTS

This work has been supported by the KiKa Foundation (Children Cancer Free) and by Deutsche Krebshilfe (DKH) 108128, ERA-Net-TRANSCAN [01KT1310] and EEC [602856-2].

CONFLICT OF INTEREST

The funding made this study financially possible, and had no role in study design or interpretation. There were no conflicts of interest disclosures from any authors.

ORCID

Lianne M. Haveman https://orcid.org/0000-0001-8519-8906
Uta Dirksen https://orcid.org/0000-0002-5435-7860
Johannes H.M. Merks https://orcid.org/0000-0001-7659-1028

REFERENCES

1. Potratz J, Jürgens H, Craft A, Dirksen U. Ewing sarcoma: biology-based therapeutic perspectives. Pediatr Hematol Oncol. 2012;29(1):12-27.
2. Ladenstein R, Pötschger U, Le Deley MC, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010;28(20):3284-3291.
3. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000;18(17):3108-3114.
4. Picci P, Rougraff BT, Bacci G, et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma. J Clin Oncol. 2000;18(17):3108-3114.
5. Sauer R, Jürgens H, Burgers JM, Dunst J, Hawlicek R, Michaelis J. Prognostic factors in the treatment of Ewing's sarcoma. The Ewing's Sarcoma Study Group of the German Society of Paediatric Oncology CESS 81. Radiother Oncol. 1987;10(2):101-110.
6. Brisse H, Ollivier L, Edeline V, et al. Imaging of malignant tumours of the long bones in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment. Pediatr Radiol. 2004;34(8):595-605.
7. Lemmi MA, Fletcher BD, Marina NM, et al. Use of MR imaging to assess results of chemotherapy for Ewing sarcoma. AJR Am J Roentgenol. 1990;155(2):343-346.
8. van der Woude HJ, Bloem JL, Hogendoorn PC. Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing's sarcoma: review of current imaging modalities. Skeletal Radiol. 1998;27(2):57-71.

TABLE 3 Multivariate analysis by Cox regression of factors associated with disease outcome in patients with localized EwS during late induction phase (n = 175)

| Covariate                               | EFS |         |         |         | OS  |         |         |         |
|-----------------------------------------|-----|---------|---------|---------|-----|---------|---------|---------|
|                                         | HR  | 95% CI  | P       | HR  | 95% CI | P       |         |
| Age > 15 years                           | 1.04| 0.56-1.91| 0.91    | 1.36| 0.72-2.58| 0.35    |         |
| Sex                                     | 0.62| 0.32-1.19| 0.15    | 0.89| 0.47-1.70| 0.73    |         |
| Initial tumor volume > 200 mL           | 1.73| 0.91-3.30| 0.10    | 1.58| 0.81-3.11| 0.18    |         |
| Poor histological response (>10% viable cells) | 2.28| 1.25-4.15| 0.007*  | 2.23| 1.20-4.15| 0.011*  |         |
| Late inadequate tumor volume response (3D) | 2.26| 1.23-4.15| 0.008*  | 1.69| 0.89-3.2 | 0.10    |         |
| Pelvic location                          | 2.80| 1.49-5.40| 0.001*  | 2.44| 2.44-1.25| 0.01*   |         |

CI, confidence interval; HR, Hazard ratio.

*Difference P < 0.05.
9. Bloem JL, Tamminiau AH, Eulderink F, Hermans J, Pauwels EK. Radiologic staging of primary bone sarcoma: MR imaging, scintigraphy, angiography, and CT correlated with pathologic examination. *Radiology*. 1988;169(3):805-810.

10. Leung JC, Dalinka MK. Magnetic resonance imaging in primary bone tumors. *Semin Roentgenol*. 2000;35(3):297-305.

11. van der Woude HJ, Bloem JL, Holscher HC, et al. Monitoring the effect of chemotherapy in Ewing’s sarcoma of bone with MR imaging. *Skeletal Radiol*. 1994;23(7):493-500.

12. Abudu A, Davies AM, Pynsent PB, et al. Tumour volume as a predictor of necrosis after chemotherapy in Ewing’s sarcoma. *J Bone Joint Surg Br* 1999;81(2):317-322.

13. Pan HY, Morani A, Wang WL, et al. Prognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection.Int J Radiat Oncol Biol Phys 2015;1;92(2):349-357.

14. Golfieri R, Baddeley H, Pringle JS, Leung AWL, Greco A, Souhami R. MRI in primary bone tumours: therapeutic implications. *Eur J Radiol*. 1991;12:201-207.

15. Miller SL, Hoffer FA, Reddick WE, et al. Tumor volume or dynamic contrast-enhanced MRI for prediction of clinical outcome of Ewing sarcoma family of tumors. *Pediatr Radiol*. 2001;31(7):518-523.

16. Aighighi M, Boe J, Rosenberg J, et al. Three-dimensional radiologic assessment of chemotherapy response in Ewing Sarcoma can be used to predict clinical outcome. *Radiology*. 2016;280(3):905-915.

17. Juergens C, Weston C, Lewis I, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. *Pediatr Blood Cancer*. 2006;47(1):22-29.

18. Schoot RA, McHugh K, van Rijn RR, et al. Response assessment in pediatric rhabdomyosarcoma: can response evaluation criteria in solid tumors replace three-dimensional volume assessments? *Radiology*. 2013;269(3):870-878.

19. Gahan EA, Tefft MC. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? *J Natl Cancer Inst*. 2000;92(3):179-181.

20. Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma after polychemotherapy-study COSS 80. *J Cancer Res Clin Oncol*. 1983;106(Suppl):21-24.

21. Le Deley M, Paulussen M, Lewis I, et al. Cyclophosphamide compared with Ifosfamide in consolidation treatment of standard-risk Ewing Sarcoma: results of the randomized noninferiority Euro-EWING99-R1 Trial. *J Clin Oncol*. 2014;32:2440-2448.

22. Grevener K, Haveman LM, Ranft A, et al. Management and outcome of Ewing Sarcoma of the head and neck. *Pediatr Blood Cancer*. 2016;63:604-610.

23. Bedetti B, Wiebe K, Ranft A, et al. Use of MR imaging to assess results of chemotherapy for Ewing sarcoma. *AJR*. 1990;155:343-346.

24. Mac Vicar AD, Olliff JFC, Pringle J, Ross Pinkerton C, Husband JES. Ewing sarcoma: MR imaging of chemotherapy-induced changes with histologic correlation. *Radiology*. 1992;184:859-864.

25. Shapeero LG, Vanel D. Imaging evaluation of the response of high grade osteosarcoma and Ewing sarcoma to chemotherapy with emphasis on dynamic contrast-enhanced magnetic resonance imaging. *Semin Musculoskeletal Radiol*. 2000;4(1):137-146.

26. Burke M, Anderson JR, Kao SC, et al.; Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience—a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. *J Clin Oncol* 2007;25(31):4909-4913.

27. Chen L, Liu M, Bao J, et al. The correlation between apparent diffusion coefficient and tumor cellularity in patients: a meta-analysis. *PLoS ONE* 2013;8(11):e79008.

28. Bailly C, Leforestier R, Campion L, et al. Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma. *PLoS ONE*. 2017;12(8):e0183841.

29. Degnan AJ, Chung CY, Shah AJ. Quantitative diffusion-weighted magnetic resonance imaging assessment of chemotherapy treatment response of pediatric osteosarcoma and Ewing sarcoma malignant bone tumors. *Clin Imaging*. 2018;47:9-13.

30. Mozley PD, Schwartz LH, Bendtsen C, Zhao B, Petrick N, Buckler AJ. Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence. *Ann Oncol*. 2010;21(9):1751-1755.

31. Silva FD, Pinheiro L, Cristofano C, de Oliveira Schiavon JL, Lederman HM. Magnetic resonance imaging in pediatric bone tumors. *Curr Radiol Rep*. 2014;2(77):2-11.

32. Oberlin O, Deley MC, Bui BN, et al. J French Society of Paediatric Oncology. Prognostic factors in localized Ewing’s Sarcoma: results of the randomized noninferiority Euro-EWING99-R1 Trial. *J Clin Oncol*. 2014;32:2440-2448.

33. Greven K, Haveman LM, Ranft A, et al. Management and outcome of Ewing Sarcoma of the head and neck. *Pediatr Blood Cancer*. 2016;63:604-610.

23. Bedetti B, Wiebe K, Ranft A, et al. Use of MR imaging to assess results of chemotherapy for Ewing sarcoma. *AJR*. 1990;155:343-346.